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Germline mutations in PTPN11, the gene encoding the protein tyrosine phosphatase SHP-2, causeNoonan syndrome
(NS) and the clinically related LEOPARD syndrome (LS), whereas somatic mutations in the same gene contribute
to leukemogenesis. On the basis of our previously gathered genetic and biochemical data, we proposed a model
that splits NS- and leukemia-associated PTPN11 mutations into two major classes of activating lesions with dif-
ferential perturbing effects on development and hematopoiesis. To test this model, we investigated further the
diversity of germline and somatic PTPN11 mutations, delineated the association of those mutations with disease,
characterized biochemically a panel of mutant SHP-2 proteins recurring in NS, LS, and leukemia, and performed
molecular dynamics simulations to determine the structural effects of selected mutations. Our results document a
strict correlation between the identity of the lesion and disease and demonstrate that NS-causative mutations have
less potency for promoting SHP-2 gain of function than do leukemia-associated ones. Furthermore, we show that
the recurrent LS-causing Y279C and T468M amino acid substitutions engender loss of SHP-2 catalytic activity,
identifying a previously unrecognized behavior for this class of missense PTPN11 mutations.
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The PTPN11 gene (MIM 176876) encodes SHP-2, a
cytoplasmic protein tyrosine phosphatase (PTP) char-
acterized by two tandemly arranged Src homology 2
(SH2) domains at the N-terminus, a catalytic domain,
and a C-terminal tail containing a proline-rich region
and two tyrosyl residues that undergo reversible phos-
phorylation (Neel et al. 2003). SHP-2 is a critical com-
ponent of signal transduction for several growth fac-
tor–, hormone-, and cytokine-signaling pathways con-
trolling developmental processes (Tang et al. 1995; Sax-
ton et al. 1997, 2000; Qu et al. 1998; Chen et al. 2000)
and hematopoiesis (Qu et al. 1997, 1998, 2001), as well
as energy balance and metabolism (Zhang et al. 2004).
Consistent with the crucial role of SHP-2 in develop-
ment, germline missense mutations in PTPN11 cause
Noonan syndrome (NS [MIM 163950]) (Tartaglia et al.
2001), a developmental disorder characterized by short
stature, facial dysmorphisms, skeletal and hematolog-
ical defects, and cardiovascular abnormalities (Noonan
1968; Allanson 1987). Accumulating genetic, modeling,
and biochemical data indicate that PTPN11 mutations
account for ∼50% of affected individuals and promote
SHP-2 gain of function (Tartaglia and Gelb 2005b).
Germline lesions in PTPN11 have also been identiﬁed
in the clinically related LEOPARD syndrome (LS [MIM
151100]) (Digilio et al. 2002; Legius et al. 2002), with
two amino acid substitutions (Y279C and T468M) oc-
curring in the vast majority of subjects (Tartaglia and
Gelb 2005b). Before the study described in this article,
there was no information regarding the consequences of
LS-causing PTPN11 mutations on the function of SHP-
2.
Children with NS are prone to developmalignancies—
most commonly, juvenile myelomonocytic leukemia
(JMML [MIM 607785]), a myeloproliferative disorder
of childhood (Emanuel 2004). Since excessive signaling
through the RAS/MAPK pathway has been implicated
in a wide variety of cancers and because SHP-2 is a
positive modulator of RAS signaling (Neel et al. 2003;
Tartaglia et al. 2004b), it was consistent that germline
PTPN11 mutations were present in children with NS
and JMML (NS/JMML) (Tartaglia et al. 2003). More-
over, somatic missense mutations in PTPN11 have been
documented with variable prevalence in a heterogeneous
group of hematologic malignancies (Tartaglia et al.
2003, 2004a, 2005; Loh et al. 2004a, 2004b, 2005) and
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Table 1
SHP-2 Affected Residues and Amino Acid Changes
Germinally Transmitted or Somatically Acquired
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
solid tumors (Bentires-Alj et al. 2004). Similar to what
was observed for NS, genetic, biochemical, and func-
tional data support the view that acquired lesions con-
tributing to leukemia promote SHP-2 gain of function
(Tartaglia et al. 2003; Chan et al. 2005; Keilhack et al.
2005; Mohi et al. 2005; Shubbert et al. 2005), providing
the ﬁrst evidence of a mutated PTP acting as an onco-
protein in cancer.
Our initial studies indicated that mutations identiﬁed
in NS (germline origin) and leukemia (somatic origin)
rarely overlap (Tartaglia et al. 2003). On the basis of
those results, we proposed a model requiring at least
two classes of activating mutations of PTPN11 with
different roles in development and leukemogenesis. A
third class, as-yet functionally uncharacterized, would
include a few mutations, including the recurrent LS-
causing lesions, which affect residues clustering within
or in proximity to the active site of the protein and are
predicted to impair catalysis. To test this model, we in-
vestigated the diversity and structural consequences of
germline and somatic PTPN11 mutations, delineated
their association with disease, and characterized bio-
chemically and structurally a panel of amino acid
changes recurring in NS, LS, and leukemia that affect
distinct functional domains of the protein.
Material and Methods
Subjects
Two large cohorts containing subjects with NS or LS who
might have germline PTPN11 mutations ( ) and thoseNp 425
with hematologic malignancies ( ) who might haveNp 303
somatic ones were included in the study. For the NS/LS cohort,
there were two groups. For one ( ), subjects were en-Np 116
rolled in research protocols. Clinical features for the majority
of these individuals satisﬁed the diagnostic criteria reported by
van der Burgt et al. (1994) or Voron et al. (1976), but indi-
viduals who lacked sufﬁcient features to receive a deﬁnitive
diagnosis were also included in the study. The second group
( ) comprised mutation data from anonymous samplesNp 309
from individuals with phenotypes suggestive of NS or LS and
prompting commercial DNA diagnostic testing at GeneDx
(Gaithersburg, MD); no phenotype data were available for
these persons. In the leukemia cohort, which included 63 chil-
dren with JMML, 147 adult subjects with acute myeloid leu-
kemia (AML), and 93 adult subjects with acute lymphoblastic
leukemia (ALL), diagnosis was established according to stan-
dard morphologic, cytochemical, and immunological criteria
(Bene et al. 1995; Emanuel 2004) and was centrally reviewed
(R.F., C.S., and P.D.E.). All nonanonymous samples were col-
lected under institutional review board–approved protocols
and with informed consent.
Molecular Analysis and Data Collection
Genomic DNA was isolated from peripheral blood lympho-
cytes (NS/LS) or from bone marrow aspirates (leukemias) ob-
tained at the time of diagnosis, before therapy, as well as during
follow-up. PTPN11 mutational screening was performed by
denaturing high-performance liquid chromatography analysis
with the use of the Wave 2100 System (Transgenomics) at
column temperatures recommended by the Navigator version
1.5.4.23 software (Transgenomics), as described elsewhere
(Tartaglia et al. 2002, 2004a). Amplimers having abnormal
denaturing proﬁles were puriﬁed (Microcon PCR [Millipore])
and were sequenced bidirectionally with the use of the ABI
BigDye Terminator Sequencing Kit v.1.1 (Applied Biosystems)
and an ABI Prism 310 Genetic Analyzer (Applied Biosystems).
Length and dinucleotide mutations were determined by cloning
puriﬁed PCR products in a pCR 2.1 TOPO vector (Invitrogen)
and sequencing puriﬁed clones (Plasmid Mini Kit, Qiagen).
The entire PTPN11 coding sequence was screened in the NS/
LS cohort. On the basis of our previously generated data, exons
1, 2, 3, 4, 7, 8, 12, 13, and 14—encompassing all the PTPN11
lesions identiﬁed in NS, LS, and leukemias—were screened in
the leukemia cohort.
Germline and somatic PTPN11 mutations reported in stud-
ies published (or available online as preprint versions) before
September 2005 were collected. In the resulting database,
germline mutations referred to lesions identiﬁed in subjects
with a developmental disorder (NS, LS, or a related condition),
whereas somatic mutations referred to defects identiﬁed in sub-
jects with isolated hematologic malignancies, preleukemic dis-
orders, or solid tumors. The database and relative references
are reported in table 1.
Biochemical Studies
Full-length human His-tagged PTPN11 cDNA cloned in
pET-26b (Novagen) was a kind gift from Antonio Pizzuti (De-
partment of Experimental Medicine and Pathology, University
La Sapienza, Rome). The single nucleotide changes resulting
in T42A, A72S, A72V, T73I, E76D, E76K, E139D, Y279C,
I282V, N308D, T468M, M504V, and C459G were introduced
by site-directed mutagenesis (QuikChange Site-Directed Mu-
tagenesis Kit [Stratagene]). Recombinant SHP-2 proteins were
expressed in Escherichia coli Rosetta 2 (DE3) competent cells
(Novagen). After induction, harvesting, and cell lysis, proteins
were puriﬁed by chromatography with the use of Ni-NTA
magnetic agarose beads (Qiagen) (ﬁg. 1). In vitro phosphatase
assays were performed using 20 pmol of puriﬁed recombinant
SHP-2 proteins in 200 ml of PTP buffer (25 mM Hepes, pH
7.4; 50 mM NaCl; 2.5 mM EDTA; 60 mg/ml BSA; and 5 mM
dithiothreitol) supplemented with 20 mM of paranitrophenyl
phosphate (pNPP) (Sigma) as substrate, either in basal con-
dition or with the activating PTP nonreceptor type substrate
1 (PTPNS1) (DITpYADLNLPKGKKPAPQAAEPNNHTEpY-
ASIQTS-NH2) (Primm) bisphosphoryl tyrosine-based activa-
tion motif (BTAM) peptide (10 mM), and incubated for 30 min
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Figure 1 Coomassie-stained SDS polyacrylamide gel showing
purity of the wild-type and mutated SHP-2 proteins expressed in E.
coli Rosetta 2 (DE3) cells and utilized in phosphatase assay experi-
ments. The legend is available in its entirety in the online edition of
The American Journal of Human Genetics.
at 30C. Reactions were stopped by the addition of 800 ml of
0.1N NaOH. pNPP dephosphorylation was evaluated by mea-
suring absorbance at 410 nm. Amount, purity, and integrity
of recombinant SHP-2 proteins were evaluated using the Pro-
tein Assay Kit (Bio-Rad), Coomassie staining, and immunoblot
analysis with anti–SHP-2 monoclonal antibody (Santa Cruz
Biotechnology).
Transfections in COS1 cells and immunoprecipitations were
performed as described elsewhere (Tartaglia et al. 2003; Fra-
gale et al. 2004). Phosphatase assays using immunocomplexes
were performed using pNPP as substrate, basally or after
BTAM peptide stimulation.
Molecular Dynamics Simulations
Initial coordinates of human SHP-2 were taken from the x-
ray crystal structure (Hof et al. 1998) (PDB entry 2shp, chain
A). The program DeepView 3.7 (Guex and Peitsch 1997) was
used to determine the conformation of missing loops in SHP-
2 crystal structure by homology modeling and to introduce
residues T2, F41, and F513 and the disease-causing amino acid
substitutions after an analysis of all possible rotamers of the
side chains. The same program was used to add polar and
aromatic hydrogen atoms, providing the initial coordinates of
the complete chain from residue 2 to 525.
Molecular dynamics (MD) simulations were performed us-
ing GROMACS 3.1.4, with the ffgmx force ﬁeld (Lindhal et
al. 2001). The simulations were performed as described else-
where (Stella et al. 1999), except for the following details. After
energy minimization in vacuo, the protein was centered in a
triclinic box (6.4#8.5#8.7 nm) and was hydrated using the
simple point charge water model (Berendsen et al. 1981),main-
taining the water molecules included in the crystallographic
structure and located within 0.5 nm of the protein. The ﬁnal
fully hydrated system contained 113,000 water molecules. Ini-
tial strains in the system were released by a two-step energy
minimization and a 100-ps MD simulation with protein atoms
(except those belonging to mutated or modeled residues) po-
sition restrained. The system was kept at a constant temper-
ature (300 K) and pressure (1 bar) by the Berendsen weak-
coupling method (Berendsen et al. 1984), with the use of
separate temperature baths for protein and solvent and with
a relaxation time of 0.1 ps for temperature and 1 ps for pres-
sure. Nonbonded interactions were treated in accordance with
the twin-range method (cut-off radii of 1 nm and 1.5 nm).
The simulated trajectory was 5.3 ns long in the case of mu-
tant E76K and 9.8 ns long for mutants E76D, A72V, andA72S.
Two simulations were performed for the wild-type protein,
differing for the random initial velocities: 5.3 ns long (indicat-
ed as WT_s) and 9.8 ns (WT_l). These calculations were per-
formed on the computer cluster of the E. Fermi Research Cen-
ter of Rome (32 Pentium IV nodes interconnected through
Myrinet 2000).
Molecular graphics and solvent-accessible surface calcula-
tions were performed with MOLMOL software (Koradi et al.
1996). H-bonds were assigned in accordance with standard
GROMACS criteria. Root mean square positional deviations
(RMSD) were calculated according to the following deﬁnition:
N1 2 [ ]RMSD(t)p r(t) r(0) , i iN ip1
where the summation runs over the N atoms of the N-SH2
loop (residues 58–62), is the positional vector of atom ir(t)i
at time t, and is its position in the initial structure (Stellar(0)i
and Melchionna 1998). Translational and rotational motions
of the protein were removed by ﬁtting the positions of the PTP
signature motif atoms (residues 457–467) to their coordinates
in the initial structure. In this way, the differences in the RMSD
values were due to both the internal conformational changes
of the N-SH2 loop and the relative motions between this loop
and the PTP active site.
Results
Diversity of Germline and Somatic PTPN11 Mutations
Heterozygous germline PTPN11mutations were iden-
tiﬁed in 204 individuals with NS or LS and constituted
47 molecular lesions, including six novel defects (table
2). None of the mutations was observed in 300 unaf-
fected individuals of European descent. Parental DNA
specimens were available for 47 families with both un-
affected parents and for 17 families transmitting the dis-
order. In these cases, testing of DNAs demonstrated ei-
ther the de novo origin of the mutation (including the
previously unreported 179delGTGAinsT and 184TrA)
or cosegregation with disease (including the novel
802GrA and 854TrG). Parental DNA specimens were
not available to conﬁrm the de novo origin of the novel
172ArC and 802GrT changes, but both of the affected
residues (N58 and G268) are mutated in other NS cases,
supporting a pathogenic role for the variants. Consistent
with our previous data, the vast majority ofNS-causative
mutations were missense and preferentially affected ex-
ons 3 and 8.
The present data and available published records (up-
dated to August 2005) were utilized to analyze the di-
versity of germline mutations and to classify them on
the basis of their predicted effect on protein function.
SHP-2 switches between inactive and active conforma-
tions, depending on its binding to phosphotyrosyl (pY)–
containing signaling partners. In the unliganded inactive
conformation, the N-SH2 domain interacts extensively
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Table 2
List of Germline PTPN11 Mutations Identiﬁed in 204 Subjects with
NS or LS
Predicted Amino
Acid Change
No. of
Cases
Nucleotide
Substitution Exon Domain
T2I 1 5CrT 1 N-SH2
T42A 3 124ArG 2 N-SH2
N58H 1 172ArCa 3 N-SH2
N58D 1 172ArG 3 N-SH2
N58K 1 174CrG 3 N-SH2
G60A 4 179GrC 3 N-SH2
G60VdelD61 1 179delGTGAinsTa 3 N-SH2
D61N 5 181GrA 3 N-SH2
D61G 9 182ArG 3 N-SH2
Y62N 1 184TrAa 3 N-SH2
Y62D 4 184TrG 3 N-SH2
Y63C 12 188ArG 3 N-SH2
A72S 9 214GrT 3 N-SH2
A72G 6 215CrG 3 N-SH2
T73I 3 218CrT 3 N-SH2
E76D 7 228GrC 3 N-SH2
E76D 1 228GrT 3 N-SH2
Q79R 9 236ArG 3 N-SH2
D106A 2 317ArC 3 Linker
E110A 1 329GrC 3 Linker
E139D 8 417GrC 4 C-SH2
E139D 2 417GrT 4 C-SH2
Q256R 2 767ArG 7 PTP
G268S 1 802GrAa 7 PTP
G268C 1 802GrTa 7 PTP
Y279C 10 836ArG 7 PTP
Y279S 1 836ArC 7 PTP
I282V 4 844ArG 7 PTP
F285C 1 854TrGa 8 PTP
F285S 2 854TrC 8 PTP
N308D 40 922ArG 8 PTP
N308S 13 923ArG 8 PTP
N308T 2 923ArC 8 PTP
I309V 1 925ArG 8 PTP
G464A 1 1391GrC 12 PTP
T468M 14 1403CrT 12 PTP
P491S 2 1471CrT 13 PTP
P491L 2 1472CrT 13 PTP
S502A 1 1504TrG 13 PTP
S502T 2 1504TrA 13 PTP
S502L 1 1505CrT 13 PTP
G503R 2 1507GrA 13 PTP
G503R 3 1507GrC 13 PTP
M504V 2 1510ArG 13 PTP
Q506P 2 1517ArC 13 PTP
Q510E 2 1528CrG 13 PTP
Q510P 1 1529ArC 13 PTP
a Novel mutation.
Table 3
Classiﬁcation and Relative Distribution of Germline and Somatic
PTPN11 Mutations
MUTATION
GROUP
PREDICTED EFFECT ON
SHP-2 FUNCTIONa
GERMLINE
ORIGIN
( )Np 573
SOMATIC
ORIGIN
( )Np 256
N % N %
I A/I switching 243 42.4 217 84.8
II A/I switching and catalysis 66 11.5 3 1.2
III A/I switching and speciﬁcity 27 4.7 27 10.5
IV A/I switching and/or catalysis 195 34.0 4 1.6
V SH2 pY-binding 28 4.9 5 1.9
VI SH2 orientation or mobility 12 2.1 … …
Others … 2 .4 … …
a A/I p Active/inactive conformation.
with the PTP domain, blocking the active site (Hof et
al. 1998). Binding of an exposed pocket of the N-SH2
to a pY-containing peptide promotes a conformational
change of the domain, leading to the disruption of the
N–SH2/PTP interaction and to the activation of the
phosphatase. According to this allosteric mechanism of
activation and the crystallographic structure of the pro-
tein, and taking into account conserved structural and
functional features of SH2 (Bradshaw and Waksman
2002) and PTP (Andersen et al. 2001) domains, the
PTPN11 germline mutations (62 distinct amino acid
changes or small inframe deletions documented in 573
subjects; see table 1) were classiﬁed into sixmajor groups
(table 3 and ﬁg. 2A). Group I included lesions affecting
residues located in or close to the N–SH2/PTP–inter-
acting surface with no direct role in catalysis (T2, N58,
G60, D61, Y62, Y63, E69, F71, A72, T73, E76, Q79,
and Q256). Such lesions are predicted to perturb the
equilibrium between the inactive and active confor-
mation of the protein. The next two groups included
changes affecting surface-exposed PTP residues contrib-
uting to the stability of the catalytically inactive con-
formation but also participating in catalysis (group II:
Y279, I282, A461, and G464 at the pY-recognition site;
Q506 and Q510 in the Q loop) or controlling substrate
speciﬁcity (group III: G502 and G503). These mutations
are predicted to perturb SHP-2 switching between its
catalytically inactive and active conformation and/or its
catalytic activity/substrate speciﬁcity. Group IV included
mutations affecting residues not contributing signiﬁ-
cantly to the N–SH2/PTP interaction nor to the catalytic
function directly but either with a role in maintaining
the overall PTP structure (F285, N308, I309, and P491)
or interacting with residues participating in catalysis
(G268, T468, R498, R501, and M504). Group V in-
cluded mutations affecting residues located at the phos-
phopeptide-binding cleft of each SH2 domain (A42,
L43, and E139), which are implicated in the intermo-
lecular interactions of the protein with its signaling part-
ners and which control SHP-2 translocation and acti-
vation. Mutations affecting these pockets are predicted
to perturb phosphopeptide-binding speciﬁcity and/or af-
ﬁnity. Finally, group VI included lesions affecting resi-
dues located in the linker stretch connecting the N-SH2
and C-SH2 domains (D106 and E110). These residues
interact with residues of both SH2 domains and are pre-
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Figure 2 Germline and somatic PTPN11 mutations in human disease. A, Location of mutated residues in the three-dimensional structure
of SHP-2 in its catalytically inactive conformation (green, N-SH2 domain; cyan, C-SH2 domain; pink, PTP domain). Residues affected by
germline (left) or somatically acquired (right) mutations are shown with their lateral chains colored according to the proposed classiﬁcation
(red, group I; yellow, group II; green, group III; cyan, group IV; orange, group V; violet, group VI; blue, unclassiﬁed). B, In vitro phosphatase
assay of wild-type and mutated SHP-2 proteins. The C459G mutant is a catalytically inactive protein used as negative control. Activity was
measured as picomoles of phosphate released, with the use of pNPP as substrate in basal (white bars) and BTAM peptide-stimulated (black
bars) conditions. Values are means SDs of at least four independent experiments and are normalized to unstimulated wild-type SHP-2.
dicted to alter their relative orientation or mobility. Two
mutations, T411M and L560F, did not ﬁt rationally into
any of the groups. T411 maps onto the PTP surface but
resides far from the N–SH2/PTP–interacting region and
active site. No structural data are available for residue
L560, which maps within the proline-rich domain in the
C-terminal tail.
Mutational screening of bone marrow specimens from
303 pediatric or adult subjects with hematologic malig-
nancies identiﬁed 36 subjects with PTPN11 mutations
constituting 16 distinct lesions, including 2 that were
previously unreported (table 4). All mutations affected
exons 3 or 13 and were missense defects. With the ex-
ception of a 1507GGrCT dinucleotide change identiﬁed
in a single AML case, all mutations were single-nucle-
otide substitutions. Analysis of available DNAs from
bone marrow samples obtained during disease remission
demonstrated absence of the mutated allele in all cases,
providing evidence that mutations were somatic events
acquired in the leukemic clones. None of these defects
was observed in control DNAs.
The vast majority of somatic mutations associated
with malignancies (see table 1) altered group I residues
(N58, G60, D61, Y63, E69, F71, A72, T73, E76, and
L77) (table 3 and ﬁg. 2A). Among the remaining lesions,
nine different changes affected group III residues (S502
and G503), whereas only a few uncommon amino acid
substitutions involved group II (T507 and Q510), group
IV (R289 and P491), or group V (T52, H53, R138, and
E139) residues.
Genotype-Phenotype Correlation
The present data and available published records (see
table 1) were utilized to explore genotype/phenotype re-
lationships. Indeed, a correlation between individual
amino acid substitution and disease was observed. Spe-
ciﬁcally, two-thirds of the residues altered by one or
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Table 4
List of Somatic PTPN11 Mutations Identiﬁed in 36 Subjects
with Hematologic Malignancies
Predicted Amino
Acid Change
No. of
Cases
Nucleotide
Substitution Exon Domain
D61Y 4 181GrT 3 N-SH2
D61V 3 182ArT 3 N-SH2
A72T 4 214GrA 3 N-SH2
A72V 2 215CrT 3 N-SH2
T73I 2 218CrT 3 N-SH2
E76K 6 226GrA 3 N-SH2
E76Q 2 226GrC 3 N-SH2
E76G 5 227ArG 3 N-SH2
E76A 1 227ArC 3 N-SH2
E76V 1 227ArT 3 N-SH2
L77V 1 229TrGa 3 N-SH2
S502T 1 1504TrA 13 PTP
G503R 1 1507GrA 13 PTP
G503L 1 1507GGrCTa 13 PTP
G503E 1 1508GrA 13 PTP
G503A 1 1508GrC 13 PTP
a Novel mutation.
more PTPN11 mutations were associated only with
germline (NS or LS) or somatically acquired (malignan-
cies) disorders. Among these amino acid residues, a rel-
ative few (T42, Y62, Q79, D106, Y279, I282, F285,
N308, T468, and M504) constituted ∼50% of the total
germline events. Among the one-third of residues for
which substitutions were associated with both classes of
disorders, there was almost complete speciﬁcity between
the precise amino acid substitution and disease. Excep-
tions to this were the G60A, D61N/G, Y63C, E139D,
S502T, and G503R substitutions, which showed an un-
ambiguous predominance of germline origin (135/573
vs. 9/256; , ), and the F71L (1/5732x p 49.53 P ! .001
vs. 4/256), T73I (21/573 vs. 6/256), P491S/L (8/573 vs.
3/256), and S502A/L (4/573 vs. 3/256) changes. Signif-
icantly, T73I had been identiﬁed rarely in subjects with
NS without JMML (∼2% of cases), while it represented
the most common lesion among infants and young chil-
dren with NS associated with this myeloproliferative dis-
ease (∼50% of cases) (Kratz et al. 2005). These obser-
vations indicate that subjects carrying the T73I sub-
stitution are at risk for developing myeloproliferative
disorders. Since the myeloproliferative disorder observed
in infants and children with NS may regress without
treatment (Bader-Meunier et al. 1997; Fukuda et al.
1997; Choong et al. 1999; Yoshida et al. 2004b; Jong-
mans et al. 2005), these data also suggest that a transient
myeloproliferative condition might represent an unre-
cognized feature in young subjects with NS carrying this
amino acid change. Overall, the accumulated genetic
data strongly support the idea that the germline-trans-
mitted PTPN11 mutations have different effects on de-
velopment and hematopoiesis than those acquired
somatically.
Biochemical Analysis
To explore the consequences of germline (NS- and LS-
associated) and somatic (leukemia-associated) PTPN11
mutations on SHP-2 function, wild-type and 12 mutant
SHP-2 proteins were expressed in bacteria, and their
phosphatase activities were compared basally and after
stimulation with BTAM peptide (ﬁg. 2B). The T42A,
A72S, E76D, E139D, I282V, N308D, and M504V mu-
tations were selected to represent germline defects re-
current in NS and belonging to different mutation
groups (see above). The A72V and E76K changes are
among the most common lesions speciﬁcally associated
with leukemia and were selected for direct comparison
with the NS-causing A72S and E76D lesions, respec-
tively. Y279C and T468M were included as represen-
tative for LS, since they account for the majority of those
cases. Finally, the T73I change was included because of
its speciﬁc association with NS/JMML (see above).
Overall, these mutants can be considered as represen-
tative of the majority of germline and somatic SHP-2
defects identiﬁed in human disease thus far.
Under basal conditions, recombinant wild-type SHP-
2 exhibited a relatively low catalytic activity. Addi-
tion of SH2 domain-binding peptide (phosphorylated
PTPNS1 BTAM motif) (O’Reilly et al. 2000) promoted
a twofold increase in substrate dephosphorylation. The
leukemia-associated mutants, A72V and E76K, exhib-
ited highest phosphatase activities in both basal and
stimulated conditions. E76K showed the highest basal
activation (ninefold higher than wild-type SHP-2),
whereas A72V and E76K activities were comparable af-
ter stimulation with BTAM peptide. Similarly, the NS-
causative mutants from group I (A72S and E76D) and
group II (I282V) were basally activated. A lower but
statistically signiﬁcant higher basal phosphatase activity
was also documented for the N308D mutant (group IV)
compared with the wild-type protein (unpaired t test,
). All of these mutants also exhibited a statisti-P ! .05
cally signiﬁcant higher phosphatase activity after stim-
ulation (in all comparisons, ). Of note, the phos-P ! .001
phatase activities of these four NS-causative mutants
were signiﬁcantly lower than those of the leukemia-as-
sociated mutants basally ( , in all comparisons) asP ! .01
well as after activation with BTAM peptide ( , inP ! .05
all comparisons). The NS/JMML mutant, T73I, showed
a basal catalytic activity within the range of those ob-
served for the four NS mutants but after stimulation
displayed a dramatic increase in phosphatase activity
that was comparable to that observed in leukemia-as-
sociated mutants. Both of the group V mutants, T42A
and E139D, exhibited basal activities comparable to
those observed for wild-type SHP-2 but were more
activated after BTAM stimulation (approximately two-
fold and fourfold higher, respectively, than the wild-type
protein). Increased activation after stimulation was also
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Figure 3 Impaired phosphatase activity of the Y279C and
T468M SHP-2 mutants expressed in COS1 cells. The legend is avail-
able in its entirety in the online edition of The American Journal of
Human Genetics.
observed for the M504V mutant (group IV), which,
however, exhibited lower basal catalytic activity than
wild-type protein ( for both comparisons). Re-P ! .01
markably, extremely low phosphatase activities were
documented for the LS-associated Y279C (group II)
and T468M (group IV) mutants in both basal and stim-
ulated conditions. Of note, both the Y279C and T468M
SHP-2 proteins appeared to be responsive to BTAM
stimulation ( for both comparisons). A similarP ! .001
behavior for these mutants was also observed in phos-
phatase assays using SHP-2 immune complexes obtained
from transiently transfected COS1 cells (ﬁg. 3).
MD Simulations
To investigate the effects of the A72S, A72V, E76D,
and E76K changes on SHP-2 structure, we performed
MD simulations. The N-SH2 loop (residues 58–62) has
a major role in controlling SHP-2 catalytic activation,
by blocking the active site (Hof et al. 1998). Remarkably,
both the leukemia-associated A72V and E76K mutants
displayed a pronounced displacement of this loop from
its initial position in the crystallographic structure of the
inactive conformation (ﬁg. 4A). A quantitative measure
of this motion is provided by the RMSD of N-SH2 loop
atoms from their starting coordinates (ﬁg. 4B). In con-
trast, simulations relating with the NS-causing A72S and
E76D mutants did not show any signiﬁcant difference
from the trajectories observed in the wild-type protein
during the 10-ns time range accessible to our simula-
tions. The N-SH2 loop displacement observed for the
leukemia-associated mutants was mainly due to a col-
lective motion of the regulatory domain with respect to
the active site rather than due to a local rearrangement
of the N-SH2 structure. No effect of the mutations on
the overall conformation of this domain nor on the struc-
ture of the phosphopeptide-binding pocket was observed
(data not shown). In the case of the E76K protein, the
mutation changed an attractive electrostatic interaction
between this residue and the catalytic domain into a
repulsive strain, which slowly relaxed during the sim-
ulated trajectory as the N-SH2 and PTP domains drifted
apart. This interdomain motion caused a signiﬁcant in-
crease in solvent-accessible surface of the PTP active site
(ﬁg. 4C). In the case of the A72V protein, the mutation
induced an unfavorable steric repulsion between V72
and residues I282, I463, S502, G503, and Q506 of the
PTP domain. Relaxation of this strain caused a rear-
rangement of the interdomain orientation and a con-
sequent displacement of the N-SH2 loop from its po-
sition. This structural change resulted in a modiﬁcation
of the pattern of interactions between this loop and the
PTP domain, illustrated in ﬁgure 4D by the loss of the
hydrogen bonds connecting residues N58-Q506, G60-
Q510, and A72-Q506 during the simulated trajectory.
Remarkably, neither the E76K nor the A72V mutation
induced any intradomain stress (data not shown), which
explains the lack of signiﬁcant structural perturbations
in the N-SH2 domain.
Discussion
In the present article, we provided a more-complete as-
sessment of the diversity of germline and somatically
acquired PTPN11 lesions, developed a classiﬁcation of
mutations based on the predicted role of affected resi-
dues, evaluated their associations with disease, and in-
vestigated their structural and functional consequences
on SHP-2 function. In combination with data from pre-
vious surveys, our ﬁndings indicate that oncogenic and
NS/LS–causing PTPN11 mutations are almost always
missense changes, although small inframe deletions af-
fecting N-SH2 residues exposed towards the PTP surface
occur in a small number of cases. Available records based
on 829 germline and somatic defects revealed a complete
absence of nonsense, frameshift, and splicing defects in
NS or in contributing to oncogenesis. Moreover, this
study strongly indicated that speciﬁcity in the amino acid
substitution is relevant to the functional deregulation of
SHP-2 and disease pathogenesis. Speciﬁcally, an invar-
iant amino acid change is observed for several residues
(T42, Y63, T73, D106, E139, I282, T468, M504, and
Q506; approximately one-fourth of total events), sug-
gesting a speciﬁc role for the substituted residue. Simi-
larly, particular amino acid substitutions were speciﬁ-
cally or preferentially associated with NS, LS, or ma-
lignancy, as observed for lesions involving T42, N58,
G60, D61, Y62, Y63, E69, A72, E76, Q79, D106, E139,
Q256, Y279, I282, F285, D308, T468, G503, M504,
Q506, and Q510. On the other hand, the identity of
substitution does not seem to be critical in a few cases,
suggesting a crucial role in the function of SHP-2 for
the amino acid residue being replaced (Y62, Q79, Q256,
G268, Y279, F285, N308, and R498).
Comparison of the molecular spectrum peculiar to
the germinally transmitted and somatically acquired
PTPN11 mutations conﬁrmed previous data from our
group and from others indicating a clear-cut genotype/
phenotype correlation (Tartaglia and Gelb 2005a). In-
deed, the currently available data indicate that leukemia-
associated mutations rarely occur as germline events in
NS or LS, suggesting that these lesions might either be
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Figure 4 MD simulations. A, Comparison between the crystallographic structure of SHP-2 (gray) and the conformation attained at the
end of simulations by the E76K (blue) and A72V (red) SHP-2 mutants. The N-SH2 domain and the signature motif of the PTP domain (residues
457–467) are depicted with a ribbon representation. B, RMSD of the N-SH2 loop (residues 58-62) from its starting position. Translational and
rotational motions of the protein were removed by ﬁtting the positions of the PTP signature motif atoms to their coordinates in the initial
structure. A72V (red), A72S (green), E76K (blue), E76D (cyan), and wild-type (light and dark gray) SHP-2 proteins. C, Electrostatic energy
between residue 76 and the PTP domain (upper panel) and solvent-accessible surface area of the PTP signature motif (lower panel) during
simulations with the E76K (blue) and wild-type (black) SHP-2 proteins. D, Time behavior during simulations of the H-bonds between residues
N58-Q506, G60-Q510, and A72-Q506, contributing to stabilize the interaction between the N-SH2 loop and the PTP active site, in the A72V
(red) and wild-type (black) SHP-2 proteins.
associated with clinically distinct developmental disor-
ders or severely affect fetal development. Since fetal le-
thality is documented in NS, we prefer the latter hy-
pothesis and predict a higher prevalence of leukemia-
associated mutations among miscarried fetuses with fea-
tures suggestive of NS. Moreover, consistent with the
observation that JMML, ALL, and AML represent un-
common complications in NS, NS-causative PTPN11
mutations are rarely observed as somatic events con-
tributing to leukemia. Mutation data also indicate an
overlap with respect to the substitutions occurring in
subjects with NS or NS/JMML, as recently discussed by
Kratz et al. (2005). Of note, the clinical course of the
myeloproliferative disorder in NS/JMML tends to be rel-
atively benign compared with isolated JMML (Bader-
Meunier et al. 1997; Fukuda et al. 1997; Choong et al.
1999), supporting the hypothesis that these mutations
have a milder effect on myeloid precursor cell prolifer-
ation. Such a genotype/phenotype correlation supports
a model in which distinct gain-of-function thresholds for
SHP-2 might be required to induce cell-, tissue-, or de-
velopmental-speciﬁc phenotypes, each depending on the
transduction network context involved in the phenotype
(Tartaglia et al. 2003). The accumulated mutation data,
however, demonstrate that a few amino acid changes
can occur in both NS and isolated hematologic malig-
nancies. These mutations appear to be recurrent among
subjects with NS, whereas they are extremely rare in
leukemias. Exceptions to this rule are represented by the
T73I, P491S/L, and S502A/L changes, which are almost
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equally represented within the two groups. Although
functional studies are required to understand the bio-
logical relevance of these lesions in leukemogenesis, it is
possible that these mutations might contribute differ-
entially to distinct malignancies, as observed for the
P491S/L changes in ALL (Tartaglia et al. 2004a), or that
they might occur as a late event in the leukemic clone,
conferring merely an additional proliferative advantage
in a leukemic subpopulation (Tartaglia et al. 2005).
In both developmental disorders andmalignancies, the
distribution of the altered amino acid residues in SHP-
2 had a nonrandom pattern. According to the crystal-
lographic structure of SHP-2 and the proposed mecha-
nism of activation, affected residues were clustered in
six major groups. Phosphatase assays strongly supported
a gain-of-function role for a panel of mutations that can
be considered representative of the majority of NS-caus-
ative and leukemia-associated lesions and conﬁrmed pre-
vious biochemical and functional observations indicat-
ing a more-activating effect associated with the latter
(Tartaglia et al. 2003; Keilhack et al. 2005; Mohi et al.
2005; Shubbert et al. 2005).
MD simulations provided, for the ﬁrst time, direct
evidence supporting the hypothesis that mutations lead-
ing to strong basal activation, as observed among the
leukemia-associated mutants, perturb the interaction
between the N-SH2 and PTP domains, and they de-
scribed the molecular interactions leading to the dis-
placement of the N-SH2 loop from the PTP active site.
Such structural rearrangements were not observed for
the NS-causing A72S and E76Dmutants. One limitation
of this approach was that the simulated trajectories were
necessarily much shorter than the time scale of inter-
domain motions (because of the relatively large size of
SHP-2), so that the conformations attained by the mu-
tants during the simulations were not equilibrium struc-
tures. Therefore, the absence of observable effects for
the A72S and E76D SHP-2 proteins does not necessarily
imply a lack of structural effects of these lesions but
simply indicates that the N-SH2 loop displacement is
less favored, suggesting a lower potency of these lesions,
a ﬁnding that was in agreement with the activity data.
We predicted a possible negative effect on catalysis for
some of the mutations affecting residues located in or
close to the active site (groups II and IV). Biochemical
data conﬁrm such a prediction for the two common LS-
causing Y279C and T468M substitutions. T468 is ad-
jacent to the catalytic PTP-loop (residues 454–467), and
it is relatively conserved (40% identity) in human PTP
domains (Andersen et al. 2001). Since it is buried in a
densely packed region, the steric strain caused by the
T468M substitution would cause a rearrangement of the
region, including the catalytic loop. In the case of
Y279C, the comparison with the I282V mutant is illu-
minating, since these group II mutations have opposite
effects on the activity of SHP-2. Both Y279 and I282
contribute to the hydrophobic region binding the pY-
phenyl ring and interact with N-SH2 domain residues.
Consequently, loss of these residues would cause loss of
afﬁnity for the substrate and perturbation of the inter-
action between the N-SH2 and PTP domains. Sequence
comparison of human PTP domains (Andersen et al.
2001) showed, however, that Y279 is strongly conserved
(80% identity), with cysteine never observed in that po-
sition. In contrast, isoleucine and valine are almost
equally represented in position 282 along the sequence
of human PTP domains (40% and 30%, respectively).
Therefore, whereas Y279C strongly impaired catalysis,
the I282V mutation did not substantially perturb the
afﬁnity for the phosphopeptide substrate. In the I282V
mutant, protein activation by N-SH2 dissociation
prevailed.
By demonstrating that a distinct perturbing role on
SHP-2 function must be ascribed to the recurrent Y279C
and T468M mutations, the present study identiﬁed a
previously unrecognized behavior for a SHP-2 mutant.
The adverse biochemical consequences on catalytic ac-
tivity of the Y279C and T468M substitutions would
seem to imply loss of function in the pathogenesis of LS.
Of note, no developmental defect was observed in mice
heterozygous for a Shp-2 mutant unable to bind to in-
tracellular signaling partners (Shp-2D46–110) (Saxton et al.
1997) or hemizygous for Shp-2 (Shp-2/) (Arrandale et
al. 1996). Moreover, no lesion that would be expected
to eliminate SHP-2 (e.g., nonsense or frameshift muta-
tion near the N-terminus) has been observed in LS. This
genetic observation, together with the observed respon-
siveness of the Y279C and T468M mutants to BTAM
peptide, suggest that the pathogenesis of LS does not
derive simply from haploinsufﬁciency. Rather, the avail-
able data would be more consistent with a dominant
negative mechanism. Clearly, additional functional stud-
ies and a gene knock-in approach are required to elu-
cidate more fully the effects of these mutations on pro-
tein function and to evaluate if these mutants are
defective in signaling or interfere with normal SHP-2
function.
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